Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV‐infected patients experiencing prolonged virologic failure
- 13 July 2004
- journal article
- clinical trial
- Published by Wiley in Journal of Medical Virology
- Vol. 74 (1) , 21-28
- https://doi.org/10.1002/jmv.20141
Abstract
Four heavily antiretroviral‐experienced HIV‐infected patients had significant plasma HIV‐RNA reductions (>1 log) after beginning an Enfuvirtide (ENF)‐based rescue regimen. However, all had viral rebound shortly thereafter, sustaining high levels of plasma viremia over 80 weeks. These patients developed rapidly genotypic and phenotypic resistance to ENF. Mutations within the HR1 env region were selected (N43D in three and G36V/D in one), resulting in high‐level phenotypic resistance to ENF. Interestingly, two patients had a sustained CD4+ T‐cell increase and two maintained stable CD4+ T‐cell counts despite virologic failure under ENF. The possible mechanisms involved in this response were examined. Changes in virus tropism from R5 to R5/X4 were observed in two patients, in parallel with increases in ENF phenotypic resistance. Low levels of T‐cell activation, T‐cell turnover, and cytotoxic T lymphocyte (CTL) activity were found in all four patients. An overall increase in the proportion of viruses released from cells of the macrophage lineage was observed. In summary, single mutations at the HR1 env region result in significant loss of susceptibility to ENF. Despite virologic failure, these patients may maintain elevated CD4+ counts through a reduction in their overall immune activation. J. Med. Virol. 74:21–28, 2004.Keywords
Funding Information
- Comunidad Autónoma de Madrid (CAM)
- Asociación Investigación y Educación en SIDA (AIES)
- FIPSE
- Red de Investigación en SIDA (RIS project 173)
This publication has 25 references indexed in Scilit:
- Compensatory Link between Fusion and Endocytosis of Human Immunodeficiency Virus Type 1 in Human CD4 T LymphocytesJournal of Virology, 2004
- High Prevalence of M184 Mutation among Patients with Viroimmunologic Discordant Responses to Highly Active Antiretroviral Therapy and Outcomes after Change of Therapy Guided by Genotypic AnalysisJournal of Clinical Microbiology, 2003
- Prolonged CD4+Cell/Virus Load Discordance during Treatment with Protease Inhibitor–Based Highly Active Antiretroviral Therapy: Immune Response and Viral ControlThe Journal of Infectious Diseases, 2003
- Nonpathogenic SIV Infection of Sooty Mangabeys Is Characterized by Limited Bystander Immunopathology Despite Chronic High-Level ViremiaImmunity, 2003
- Baseline Susceptibility of Primary Human Immunodeficiency Virus Type 1 to Entry InhibitorsJournal of Virology, 2003
- Differences in Cellular Activation and Apoptosis in HIV-Infected Patients Receiving Protease Inhibitors or Nonnucleoside Reverse Transcriptase InhibitorsAIDS Research and Human Retroviruses, 2002
- Rate of Virological Treatment Failure and Frequencies of Drug Resistance Genotypes among Human Immunodeficiency Virus-Positive Subjects on Antiretroviral Therapy in SpainJournal of Clinical Microbiology, 2002
- CD4+T Cell Kinetics and Activation in Human Immunodeficiency Virus–Infected Patients Who Remain Viremic Despite Long‐Term Treatment with Protease Inhibitor–Based TherapyThe Journal of Infectious Diseases, 2002
- HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation TimeScience, 1996
- CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choiceNucleic Acids Research, 1994